Date: Thursday, August 6, 2020 at 8:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
Presented by SelectScience
The novel coronavirus SARS-CoV-2 pandemic has brought about an urgency to rapidly develop monoclonal antibodies (mAbs) that neutralize and inhibit this virus. These are the most readily manufacturable therapeutics that can be administered to prevent or treat COVID-19. To meet this global challenge, scientists are now pursuing diverse approaches that integrate the use of either patient B cells, yeast or phage display with cell sorting, sequencing and advanced bioinformatics to advance therapeutic mAb discovery.
Learning objectives:
Who should attend
This webinar will provide insights to researchers who want to learn how integrated approaches can be implemented to support swift therapeutic mAb discovery and validation.
Speaker
Naveen Suryadevara, PhD
Staff Scientist, Vanderbilt Vaccine Center
Vanderbilt University Medical Center
Alon Wellner, PhD
Researcher, Department of Biomedical Engineering
University of California, Irvine
Date: Thursday, August 6, 2020 at 8:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
Register NOWSource: sonybiotechnology.com